Madhur Rathi

Sir, thank you for the opportunity. I wanted to understand that in the past 3 years, we cumulatively added close to less than 100 registrations across the geography that we are, versus around 300 in the previous 3 years, between FY21 and ‘23. So, how should I look at our growth going forward because the registration pipeline is not as stron g as it was earlier, if you could help me understand?

I wanted to understand, with older molecules, I think most of our registrations are like previously like 3 years older. And there is a regulatory or scrutiny towar ds the older molecules towards newer generation molecules. So, how should I look at our business going forward? Because right now, this past 1 or 2 years, there has been Euro improvement, but volume growth is not seen in this quarter.

My second question was on the El Nino. Can we still expect that 10%-15% revenue growth even with the El Nino effect this year?